A Phase 2 Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to Evaluate Oral Ifetroban in Subjects With Symptomatic Aspirin Exacerbated Respiratory Disease (AERD)

Trial Profile

A Phase 2 Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to Evaluate Oral Ifetroban in Subjects With Symptomatic Aspirin Exacerbated Respiratory Disease (AERD)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 May 2018

At a glance

  • Drugs Ifetroban (Primary)
  • Indications Aspirin-induced asthma
  • Focus Therapeutic Use
  • Sponsors Cumberland Pharmaceuticals
  • Most Recent Events

    • 18 May 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
    • 18 May 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Apr 2019.
    • 06 Mar 2018 According to a Cumberland Pharmaceuticals media release, this follow-on Boxaban (Ifetroban) study received FDA clearance earlier in the year (2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top